Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
J Ovarian Res. 2020 Oct 19;13(1):124. doi: 10.1186/s13048-020-00729-1.
Ovarian cancer is the eighth most commonly occurring cancer in women. Clinically, the limitation of conventional screening and monitoring approaches inhibits high throughput analysis of the tumor molecular markers toward prediction of treatment response. Recently, analysis of liquid biopsies including circulating tumor DNA (ctDNA) open new way toward cancer diagnosis and treatment in a personalized manner in various types of solid tumors. In the case of ovarian carcinoma, growing pre-clinical and clinical studies underscored promising application of ctDNA in diagnosis, prognosis, and prediction of treatment response. In this review, we accumulate and highlight recent molecular findings of ctDNA analysis and its associations with treatment response and patient outcome. Additionally, we discussed the potential application of ctDNA in the personalized treatment of ovarian carcinoma. ctDNA-monitoring usage during the ovarian cancer treatments procedures.
卵巢癌是女性中第八种最常见的癌症。临床上，传统的筛查和监测方法的局限性限制了对肿瘤分子标志物的高通量分析，从而无法预测治疗反应。最近，包括循环肿瘤 DNA（ctDNA）在内的液体活检分析为各种实体瘤的癌症诊断和治疗开辟了新的个性化途径。在卵巢癌的情况下，越来越多的临床前和临床研究强调了 ctDNA 在诊断、预后和预测治疗反应方面的应用前景。在这篇综述中，我们积累并强调了 ctDNA 分析的最新分子发现及其与治疗反应和患者预后的关系。此外，我们还讨论了 ctDNA 在卵巢癌个体化治疗中的潜在应用。ctDNA 在卵巢癌治疗过程中的监测应用。
